The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus
- PMID: 28233274
- PMCID: PMC5357248
- DOI: 10.1007/s40265-017-0712-6
The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus
Abstract
The availability of over-the-counter (OTC) proton pump inhibitors (PPIs) for the short-term (2 weeks) management of frequent heartburn (≥2 days/week) has increased markedly, yet evidence-based recommendations have not been developed. A panel of nine international experts in gastroesophageal reflux disease developed consensus statements regarding the risks and benefits of OTC PPIs using a modified Delphi process. Consensus (based on ≥80% approval) was reached through multiple rounds of remote voting and a final round of live voting. To identify relevant data, the available literature was searched and summarized. Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system terminology was used to rate the quality of evidence and strength of recommendations; consensus was based on ≥2/3 agreement. After 4 rounds of review, consensus was achieved for 18 statements. Notably, the available data did not directly reflect OTC use, but instead, prescription use; therefore, extrapolations to the OTC setting were often necessary. This limitation is regrettable, but it justifies performing this exercise to provide evidence-based expert opinion on a widely used class of drugs. The panel determined that using OTC PPIs according to label instructions is unlikely to mask the symptoms of esophageal or gastric cancer or adversely impact the natural history of related precursor conditions. OTC PPIs are not expected to substantially affect micronutrient absorption or bone mineral density or cause community-acquired pneumonia, Clostridium difficile infection, or cardiovascular adverse events. However, OTC PPI use may be associated with slightly increased risks for infectious diarrhea, certain idiosyncratic reactions, and cirrhosis-related spontaneous bacterial peritonitis. The available evidence does not suggest that OTC PPI use consistent with label instructions is associated with substantial health risks. To minimize potential risks, healthcare professionals and consumers must actively participate in decision making when managing reflux-related symptoms in the self-care setting.
Conflict of interest statement
Financial support
Pfizer Consumer Healthcare provided funding for the live consensus panel meeting and provided recommendations and background information on prospective members of the panel (with final decisions determined by the co-chairs). Literature search assistance and writing/editorial assistance for the publication were provided by Dennis Stancavish, MA, and Diane Sloan, PharmD, of Peloton Advantage and were funded by Pfizer.
Potential conflict of interest
David A. Johnson, MD, is a paid consultant to Pfizer Consumer Healthcare and serves as an advisor for Pfizer. Philip O. Katz, MD, is a paid consultant to Pfizer Consumer Healthcare. David Armstrong, MA, MB BChir, has received an honorarium from Pfizer Consumer Healthcare and serves as an advisor for Pfizer. Henry Cohen, MD, has received an honorarium from Pfizer Consumer Healthcare. Brendan C. Delaney, MD, is a paid consultant to Pfizer Consumer Healthcare. Colin W. Howden, MD, has received an honorarium from Pfizer Consumer Healthcare. Peter Katelaris, MD, is a paid consultant to Pfizer Consumer Healthcare. Radu I. Tutuian, MD, PhD, has received an honorarium from Pfizer Consumer Healthcare. Donald O. Castell, MD, has no conflicts to disclose.
Research involving human participants and/or animals
This article does not contain any studies with human participants or animals performed by any of the authors.
Similar articles
-
Guidance on the use of over-the-counter proton pump inhibitors for the treatment of GERD.Int J Clin Pharm. 2011 Jun;33(3):493-500. doi: 10.1007/s11096-011-9489-y. Epub 2011 Apr 7. Int J Clin Pharm. 2011. PMID: 21472476
-
Management of reflux symptoms with over-the-counter proton pump inhibitors: issues and proposed guidelines.Digestion. 2009;80(4):226-34. doi: 10.1159/000235953. Epub 2009 Oct 16. Digestion. 2009. PMID: 19844107 Review.
-
Implications of over-the-counter proton pump inhibitors for patient counseling by pharmacists.Am J Ther. 2013 Nov-Dec;20(6):676-84. doi: 10.1097/MJT.0b013e318217a5d1. Am J Ther. 2013. PMID: 21642828 Review.
-
Overlapping approach Proton Pump Inhibitors/Nux vomica-Heel as new intervention for gastro-esophageal reflux management: Delphi consensus study.World J Gastroenterol. 2024 May 14;30(18):2467-2478. doi: 10.3748/wjg.v30.i18.2467. World J Gastroenterol. 2024. PMID: 38764766 Free PMC article.
-
Consumer use of over-the-counter proton pump inhibitors in patients with gastroesophageal reflux disease.Am J Gastroenterol. 2014 Jun;109(6):789-94. doi: 10.1038/ajg.2013.421. Am J Gastroenterol. 2014. PMID: 24896751
Cited by
-
Clostridioides difficile Infection in Liver Cirrhosis: A Concise Review.Can J Gastroenterol Hepatol. 2022 Jun 7;2022:4209442. doi: 10.1155/2022/4209442. eCollection 2022. Can J Gastroenterol Hepatol. 2022. PMID: 35711246 Free PMC article. Review.
-
The Protease Inhibitor Amprenavir Protects against Pepsin-Induced Esophageal Epithelial Barrier Disruption and Cancer-Associated Changes.Int J Mol Sci. 2023 Apr 5;24(7):6765. doi: 10.3390/ijms24076765. Int J Mol Sci. 2023. PMID: 37047737 Free PMC article.
-
Prevalence and Factors Associated With Proton Pump Inhibitors (PPIs) Use: A Cross-Sectional Study of PERSIAN Guilan Cohort Study.Health Sci Rep. 2025 Feb 19;8(2):e70494. doi: 10.1002/hsr2.70494. eCollection 2025 Feb. Health Sci Rep. 2025. PMID: 39980829 Free PMC article.
-
Country-wide medical records infer increased allergy risk of gastric acid inhibition.Nat Commun. 2019 Jul 30;10(1):3298. doi: 10.1038/s41467-019-10914-6. Nat Commun. 2019. PMID: 31363098 Free PMC article.
-
Why differences between New York and New Delhi matter in approach to gastroesophageal reflux disease.Indian J Gastroenterol. 2019 Oct;38(5):371-377. doi: 10.1007/s12664-019-00987-y. Indian J Gastroenterol. 2019. PMID: 31768894 No abstract available.
References
-
- Prilosec [package insert]. Wilmington: AstraZeneca Pharmaceuticals; 2012.
-
- Prilosec OTC [product monograph]. Cincinnati: Procter & Gamble; 2014.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical